Navigation Links
Repligen Reports Second Quarter Fiscal Year 2009 Financial Results
Date:11/6/2008

inancial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our intellectual property rights, our limited sales and manufacturing capabilities, our dependence on third-party manufacturers and value added resellers, our ability to hire and retain skilled personnel, our volatile stock price, and other risks detailed in Repligen's filings with the Securities and Exchange Commission. Repligen assumes no obligation to update any forward-looking information contained in this press release or wit
'/>"/>
SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder
2. Repligen Announces Conference Call of Second Quarter Fiscal Year 2009 Results Thursday, November 6th, 10:00 a.m. EST
3. Repligen Elects Alfred L. Goldberg, Ph.D. to the Board of Directors
4. Repligen Announces Share Repurchase Program
5. Repligen Announces Conference Call to Update Orencia(R) Lawsuit
6. Repligen Elects Earl Henry, M.D. to the Board of Directors
7. Repligen to Present at Upcoming Healthcare Conferences Wednesday, November 28th and Wednesday, December 5th
8. Repligen Reports Second Quarter Fiscal Year 2008 Financial Results
9. Stereotaxis Reports Third Quarter 2008 Financial Results
10. Volcano Reports 40 Percent Growth in Quarterly Revenues
11. Dialysis Corporation of America Reports Third Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... (PRWEB) July 10, 2014 Thousands ... gather in Copenhagen this July 13-17 to reveal ... the world closer to breakthroughs in dementia science. ... world’s largest conference of its kind. , As ... serves as a catalyst for generating new knowledge ...
(Date:7/10/2014)... York, US (PRWEB) July 10, 2014 ... , Merrill DataSite recently streamed the live webinar ‘Capitalizing ... a discussion from a group of several M&A experts ... seeing in the broader energy transaction marketplace. These experts ... and how the deal market in this sector has ...
(Date:7/10/2014)... CBPartners, a global leader in consulting ... new website. The redesigned site boasts improved navigation ... the firm’s thought pieces, blog posts, and conference presentations. ... showcase our insights, capabilities, and to provide timely updates ... Officer, Cyrus Chowdhury. “An enhanced online presence is ...
(Date:7/10/2014)... Best Drug Rehabilitation , ... family close by during a stay in rehab ... not the process is successful, has launched an ... http://www.bestdrugrehabilitation.com/success-stories/ . , The new Success Stories ... several Best Drug Rehabilitation graduates who wanted to ...
(Date:7/10/2014)... Washington, New York (PRWEB) July 10, 2014 ... firm dedicated to protecting the rights of victims ... couple has brought a lawsuit over allegations that ... her body by a power morcellator used during ... has been filed against Richard Wolf Medical Instruments ...
Breaking Medicine News(10 mins):Health News:Register to Download Merrill DataSite's Report: Capitalizing on the Shifting Sands of the Energy Market 2Health News:CBPartners Announces New Website 2Health News:Best Drug Rehabilitation Launches New Success Stories Section of Website 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 3Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 4Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 5
... In ... Dr. Abdul Rao , Chief Executive Officer and Chief Research Officer, the Institute ... cross-enterprise electronic platform for timely integration of patient-specific healthcare information. , ... (Vocus) December 14, 2009 -- In ...
... than white women to receive radiation therapy after a lumpectomy, ... to a new study by researchers at The University of ... its kind and the first to examine such racial disparities ... Cancer . It was first presented at the 2008 American ...
... technology could lead to quicker detection and treatment, study ... "nanosensors" can detect early signs of cancer in everyday ... sensors hunted for and picked up biomarkers for prostate ... of the Yale Institute for Nanoscience and Quantum Engineering ...
... SAN ANTONIO - In a large review of breast ... of Texas M. D. Anderson Cancer Center have identified ... long-associated with a favorable prognosis and multiple tumors undetected ... at the CTRC-AACR San Antonio Breast Cancer Symposium, is ...
... ... Treatment Program , ... (PRWEB) December 12, 2009 -- Eighteen year addiction ends at Narconon California Drug Treatment ... prescription drugs for the last eighteen years! Imagine finding that out just before Christmas. ...
... , MEXICO CITY, Dec. 11 Genomma Lab ... its,2010 earnings guidance. , Genomma Lab expects net ... of 2010, excluding possible acquisitions, and an EBITDA margin,between 25.0% and 26.0%, ... guidance. , The Company,s estimates are based on ...
Cached Medicine News:Health News:IWHNA CEO Abdul Rao Encourages the Use of Google Health for Establishing a Patient-Specific Comprehensive Digital Health Record Across Enterprises 2Health News:IWHNA CEO Abdul Rao Encourages the Use of Google Health for Establishing a Patient-Specific Comprehensive Digital Health Record Across Enterprises 3Health News:IWHNA CEO Abdul Rao Encourages the Use of Google Health for Establishing a Patient-Specific Comprehensive Digital Health Record Across Enterprises 4Health News:Study finds racial disparities exist in radiation therapy rates for early stage breast cancer 2Health News:Study finds racial disparities exist in radiation therapy rates for early stage breast cancer 3Health News:'Nanosensors' Spot Early Signs of Cancer 2Health News:M. D. Anderson study questions true favorability of rare breast cancer type 2Health News:Nurse Celebrates Son's Drug Addiction Recovery During Holidays 2
(Date:1/15/2014)... N.J. , Jan. 15, 2014  Celsion Corporation (the "Company") ... has received commitments from institutional investors to purchase an ... stock in an at-the-market registered direct offering, led by ... entered into definitive purchase agreements with these investors pursuant ...
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
(Date:1/15/2014)... Jan. 15, 2014  In an unprecedented effort to curb the spread ... and other transport vehicles, an advanced and portable UV germicidal lamp ... the first time. In order to prevent EMS ... pathogens, West Palm Beach Fire Rescue is ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2
... Qmed.com , the world,s only 100% qualified ... resource, today announced a new powerful business intelligence tool ... as part of its continuing commitment to provide users with ... "I am very pleased to announce that this new regulatory ...
... Mobility (USM) is excited to announce today that it has ... and merge its complex mobility business with USM. USM/TRS will ... Dana Mazer, ATP and his rehab team strengthens our position ... initiative in North Carolina. We are delighted to welcome their ...
Cached Medicine Technology:Qmed, the Leading Global MedTech Industry Resource Announces New Regulatory Tool to Streamline and Simplify the Regulatory and Product Development Process 2Qmed, the Leading Global MedTech Industry Resource Announces New Regulatory Tool to Streamline and Simplify the Regulatory and Product Development Process 3
...
Digital Ultrasonic Diagnostic Imaging System...
...
Pefakit PiCT DxS Diluent for Determination of Total Heparin...
Medicine Products: